A new gene therapy trial has treated its first patient, Nature News reports. The goal is to activate three genes that can make old cells behave more like young ones without losing their specialized functions. This technique is known as partial reprogramming. It is being tested as a possible treatment for glaucoma.
The idea is that the proteins produced by these genes will encourage regeneration of the nerve cells in the optic nerve. These cells are normally unable to regrow after damage from glaucoma. The trial is run by Life Biosciences. Earlier mouse studies activated the three genes and led to regrowth of optic nerve fibers and better vision in old mice as well as mice with glaucoma.
Safety concerns and the choice of the eye as first target
There are important safety questions around this method. Full reprogramming of cells can turn them into a stem cell like state that risks turning cancerous. Partial reprogramming is designed to avoid this by not resetting the cells completely. Some scientists point out that while animal work suggests it can be done safely, the risk of bad side effects in people is still unknown and could be high. The eye is seen as a reasonable first site for testing because it is somewhat separate from the rest of the body. Problems there would be less likely to threaten overall health than changes in other organs. The current trial will focus first on safety.
If the trial is found to be safe will researchers move on to see if it helps restore vision. If the method works, it could change how medicine views aging. Some argue that aging should be treated as a disease because many health problems come from cells wearing out over time. Partial reprogramming might offer a way to refresh cells across different organs and slow or reverse aspects of aging. At this point the technology is still early, and more work is needed to understand both its benefits and its risks in humans. This first treatment in a person represents a cautious but significant move forward in testing the idea.